C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter H—Medical DevicesPart 807—Establishment Registration and Device Listing for Manufacturers and Initial Importers of DevicesSubpart E—Premarket Notification Procedures

21 C.F.R. § 807.81 (2026)

When a premarket notification submission is required

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 cited 1985–2023 49citing cases
At a glance

Courts have cited this section in 49 opinions since 1985, 7 of them in the last five years.

(a) Except as provided in paragraph (b) of this section, each person who is required to register his establishment pursuant to § 807.20 must submit a premarket notification submission to the Food and Drug Administration at least 90 days before he proposes to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of a device intended for human use which meets any of the following criteria:

(1) The device is being introduced into commercial distribution for the first time; that is, the device is not of the same type as, or is not substantially equivalent to, (i) a device in commercial distribution before May 28, 1976, or (ii) a device introduced for commercial distribution after May 28, 1976, that has subsequently been reclassified into class I or II.

(2) The device is being introduced into commercial distribution for the first time by a person required to register, whether or not the device meets the criteria in paragraph (a)(1) of this section.

(3) The device is one that the person currently has in commercial distribution or is reintroducing into commercial distribution, but that is about to be significantly changed or modified in design, components, method of manufacture, or intended use. The following constitute significant changes or modifications that require a premarket notification:

(i) A change or modification in the device that could significantly affect the safety or effectiveness of the device, e.g., a significant change or modification in design, material, chemical composition, energy source, or manufacturing process.

(ii) A major change or modification in the intended use of the device.

(b)(1) A premarket notification under this subpart is not required for a device for which:

(i) A premarket approval application under section 515 of the act, or for which a petition to reclassify under section 513(f)(2) of the act, is pending before the Food and Drug Administration, or

(ii) There is a predetermined change control plan (PCCP) cleared under section 515C of the act, provided that the change is consistent with the PCCP.

(2) The appropriate FDA Center Director may determine that the submission and grant of a written request for an exception or alternative under § 801.128 or § 809.11 of this chapter satisfies the requirement in paragraph (a)(3) of this section.

(c) In addition to complying with the requirements of this part, owners or operators of device establishments that manufacture radiation-emitting electronic products, as defined in § 1000.3 of this chapter, shall comply with the reporting requirements of part 1002 of this chapter.

[42 FR 42526, Aug. 23, 1977, as amended at 72 FR 73601, Dec. 28, 2007; 89 FR 18792, Mar. 15, 2024]
The 20 cases that cite 21 C.F.R. § 807.81 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENBarbara Kaiser v. Johnson & Johnson, 947 F.3d 996 (7th Cir. 2020).
cites § 807.81 2×cited by 78 cases
The case’s holding
A medical device manufacturer discharges its duty to warn under the learned-intermediary doctrine by providing adequate warnings to physicians.
Later courts cite it for
“under indiana's learned-intermediary doctrine, a medical-device manufacturer can discharge the duty to warn by providing adequate warnings to physicians.” · 8 citing courts
2
GREENRiegel v. Medtronic, Inc., 451 F.3d 104 (2d Cir. 2006).
cites § 807.81 3×cited by 104 cases
Where it cites § 807.81
“” 21 C.F.R. § 807.81 (3)(i)-(ii) (emphasis added).”
The case’s holding
State common law tort claims alleging liability based on a medical device's adherence to FDA premarket approval standards are preempted by the Medical Device Amendments.
Later courts cite it for
“an expert opinion requires some explanation as to how the expert came to his conclusion and what methodologies or evidence substantiate that conclusion.” · 26 citing courts
3
GREENUnited States v. Caputo, 288 F. Supp. 2d 912 (N.D. Ill. 2003).
cites § 807.81 6×cited by 15 cases
Where it cites § 807.81
“) In particular they assert that 21 C.F.R. § 807.81 is unconstitutionally vague.”
Later courts cite it for
“arguments raised in a motion to dismiss an indictment that rely on disputed facts should be denied.” · 2 citing courts
4
GREENPhotoMedex, Inc. v. Irwin, 601 F.3d 919 (9th Cir. 2010).
cites § 807.81 3×cited by 57 cases
Where it cites § 807.81
“” 21 C.F.R. § 807.81 (a)(3). 4 An FDA guideline *926 document makes clear that responsibility is placed on the manufacturer to decide whether device changes necessitate a new 510(k) submission.”
The case’s holding
A private Lanham Act action is barred if the claim requires litigation of an underlying Food, Drug, and Cosmetic Act violation that the FDA has not concluded occurred.
Later courts cite it for
“because the fdca forbids private rights of action under that statute, a private action brought under the lanham act may not be pursued when, as here, the claim would require litigation of the alleged underlying fdca violation in a circumstance where the fda has not itself concluded that there was such a violation.” · 11 citing courts
5
GREENBarbara E. Horn v. Thoratec Corp., 376 F.3d 163 (3d Cir. 2004).
cites § 807.81 2×cited by 101 cases
Where it cites § 807.81
“Moreover, the range of changes that a manufacturer can make to a [§ 510(k) ] cleared device without getting prior authority from FDA is broader than for a[PMA] approved device.”
The case’s holding
State law failure-to-warn claims are preempted when they require a manufacturer to provide different warnings or instructions than those approved through the FDA pre-market approval process.
Later courts cite it for
“an agency may change its course so long as it can justify its change with a 'reasoned analysis.” · 3 citing courts
6
GREENUnited States v. Facteau, 89 F.4th 1 (1st Cir. 2023).
cites § 807.81 4×cited by 8 cases
Where it cites § 807.81
“21 C.F.R. § 807.81 (a). This premarket notification submission includes a "510(k) summary" identifying the predicate device and describing the device submitted for clearance, including its "intended use.”
Later courts cite it for
“make apparent his theory of the district court's plain error, and he did squarely address the plain error factors in his reply brief,” · 1 citing court
7
GREENUnited States v. Caputo, 313 F. Supp. 2d 764 (N.D. Ill. 2004).
cites § 807.81 7×cited by 6 cases
Where it cites § 807.81
“” 21 C.F.R. § 807.81 (a)(3). 2 The FDA granted Abtox premarket clearance to market the Plazlyte sterilizer after determining that it was substantially equivalent to ethylene oxide sterilizers that were already on the market.”
8
GREENUnited States v. Caputo, 517 F.3d 935 (7th Cir. 2008).
cites § 807.81 2×cited by 48 cases
Where it cites § 807.81
“The line between a “modification” (no approval needed) and a new device (which must be submitted independently for approval) is drawn in 21 C.F.R. § 807.81 . There are two principal inquiries: first, whether the changes “significantly affect the safety or effectiveness of the…”
The case’s holding
The interpretation of the meaning of statutes and regulations is a matter for the court rather than a subject for testimonial experts.
Later courts cite it for
“the only legal expert in a federal courtroom is the judge.” · 6 citing courts
9
GREENForman v. Meridian Bioscience, Inc., 387 F. Supp. 3d 791 (S.D. Ohio 2019).
cites § 807.81 2×cited by 12 cases
Where it cites § 807.81
“Nonetheless, Meridian recklessly and misleadingly stated in its November 2016 Form 10-K that all of its products, including all of the LeadCare products, were "cleared by the FDA.”
Later courts cite it for
“the term 'clear error' is not well-defined in the sixth circuit, but it does 'clearly indicate that a high standard applies.” · 7 citing courts
10
GREENNorth Am. Med. Corp. v. Axiom Worldwide, Inc., 522 F.3d 1211 (11th Cir. 2008).
cites § 807.81 1×cited by 162 cases
Where it cites § 807.81
“Compare 21 C.F.R. § 807.81 (a)(1) (2006), with 21 C.”
The case’s holding
Using a competitor's trademarks in website meta tags constitutes a use in commerce in connection with advertising if the use causes a likelihood of source confusion.
Later courts cite it for
“although ebay dealt with the patent act and with permanent injunctive relief, a strong case can be made that ebay's holding necessarily extends to the grant of preliminary injunctions under the lanham act.” · 5 citing courts
11
GREENKapps v. Biosense Webster, Inc., 813 F. Supp. 2d 1128 (D. Minn. 2011).
cites § 807.81 2×cited by 21 cases
Where it cites § 807.81
“Under 21 C.F.R. § 807.81 , a new 510(k) application is required when a manufacturer makes “[a] change or modification in [a previously approved] device that could significantly affect the safety or effectiveness of the device.”
The case’s holding
A reprocessor that conveys a used product with its own instructions, warranty, and label removal is not a mere service provider and may be liable as a manufacturer.
Later courts cite it for
“(1) the defendant had a duty to warn; (2) the defendant breached that duty by providing an inadequate warning (or no warning at all); and (3) the defendant's inadequate (or nonexistent) warning caused the plaintiff's damages.” · 2 citing courts
12
GREENUnited States ex rel. Nowak v. Medtronic, Inc., 806 F. Supp. 2d 310 (D. Mass. 2011).
cites § 807.81 1×cited by 32 cases
Where it cites § 807.81
“5 ; 21 C.F.R. § 807.97 . These limited indications must be listed on the label, and a manufacturer may only promote a device for cleared or approved indications.”
The case’s holding
Relators must allege specific details regarding each asserted state claim and cannot rely on generalized pleadings to satisfy the particularity requirements of Rule 9(b).
Later courts cite it for
“in order to satisfy rule 9(b), relators must allege some specificity with respect to each asserted state and cannot rely upon generalized pleadings.” · 3 citing courts
13
GREENGoodlin v. Medtronic, Inc., 167 F.3d 1367 (11th Cir. 1999).
cites § 807.81 1×cited by 59 cases
Where it cites § 807.81
“at 2254 ; see also 21 C.F.R. § 807.81 (a)(3) (requiring premarket notification for the reintroduction into commercial distribution of any device that is about to be significantly changed or modified).”
The case’s holding
FDA premarket approval of a medical device does not impose an ascertainable federal requirement that preempts state law product liability claims.
Later courts cite it for
“neither the fda's actual review of a device and its supporting information nor the agency's eventual approval of the device imposes any ascertainable requirement upon the device.” · 4 citing courts
14
GREENHealey v. I-Flow, LLC, 853 F. Supp. 2d 868 (D. Minn. 2012).
cites § 807.81 1×cited by 19 cases
Where it cites § 807.81
“Premarket notifications are also required both when a medical device is initially introduced into the commercial market for the first time and whenever a previously approved medical device is to be significantly modified in its intended use.”
Later courts cite it for
“our federal court utilizes section 549.191's gatekeeping procedure in diversity cases because it discourages forum shopping between state and federal court.” · 2 citing courts
15
REDLora Lohr v. Medtronic, Inc., 56 F.3d 1335 (11th Cir. 1995).
cites § 807.81 1×cited by 44 cases
Reversed in part by Medtronic, Inc. v. Lohr (1996): the U.S. Supreme Court's own opinion in this case ("VII Accordingly, the judgment of the Court of Appeals is reversed insofar as it held that any of the claims were preempted an…
Where it cites § 807.81
“, 21 C.F.R. §§ 807.81 (a)(3)® (requiring FDA approval for any design changes); 895.”
The case’s holding
The Medical Device Amendments do not preempt state law negligent design or strict liability claims for devices cleared through the 510(k) substantial equivalence process.
Later courts cite it for
“preemption under the mda cannot be defeated by a common lawsuit alleging a violation of the statutory standards” · 2 citing courts
cites § 807.81 4×cited by 4 cases
Where it cites § 807.81
“The premarket notification requirement applicable to Stryker is contained in 21 C.F.R. § 807.81 (a)(2). It provides that a person required to register, who introduces a device for the first time, must provide pre-market notification.”
17
GREENUnited States ex rel. Colquitt v. Abbott Labs., 864 F. Supp. 2d 499 (N.D. Tex. 2012).
cites § 807.81 1×cited by 15 cases
Where it cites § 807.81
“The 510(k) notice must include, among other things, proposed labeling sufficient to describe the device, its intended use, and the directions for its use; a statement indicating the device is similar to or different from other products of comparable type in commercial…”
Later courts cite it for
“(1) public disclosure; (2) in a particular form specified in. the statute; and (3) of allegations or transactions.” · 2 citing courts
cites § 807.81 1×cited by 35 cases
Where it cites § 807.81
“See also 21 C.F.R. § 807.81 (a) & 807.87(e) (exempting those who need not register with the FDA, including raw material suppliers, from obtaining clearance for, and approval of, any product warnings or labels); 21 C.”
The case’s holding
Where reasonable minds cannot differ on the adequacy of a warning, no material fact issue exists and summary judgment is proper; a warning to a sophisticated intermediary can suffice.
Later courts cite it for
“... an appellee can propose alternative grounds in support of trial court judgment so long as those arguments were presented below” · 2 citing courts
19
GREENWheat v. Sofamor, S.N.C., 46 F. Supp. 2d 1351 (N.D. Ga. 1999).
cites § 807.81 1×cited by 29 cases
Where it cites § 807.81
“81 , each person who is required to register his establishment for device listing purposes must submit a premarket notification submission to the Food and Drug Administration at least 90 days before he proposes to begin the introduction or delivery into commerce a device…”
The case’s holding
A plaintiff must prove specific causation, that the product in question caused the injury, and expert testimony lacking reasonable medical certainty on that point is inadmissible and cannot defeat summary judgment.
Later courts cite it for
“general causation is the capacity of a product to cause injury; specific causation is proof that the product in question caused the injury of which the plaintiff complains.” · 3 citing courts
20
YELLOWDuvall v. Bristol-Myers-Squibb Co., 65 F.3d 392 (4th Cir. 1995).
cites § 807.81 3×cited by 17 cases
Vacated: 2 citing opinions add another limit ("vacated (caution)").
Where it cites § 807.81
“21 C.F.R. § 807.81 (a)(3). The FDA’s determination that Bristol-Myers’ prosthesis is substantially equivalent to those previously marketed thus binds Bristol-Myers to its representations to the FDA; for all intents *400 and purposes, Bristol-Myers is required to continue to…”

Show all 49 citing cases (list view) →

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
198520042023

One bar per year. Tallest: 9 cases in 1995. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
11th Cir.57th Cir.43rd Cir.2N.D. Cal.2N.D. Ill.2N.D. Ind.2D. Kan.2D. Minn.2

The 8 courts with the most citing cases, of 32 courts in all.

By subsection

Courts have not cited this section by subsection, so its cases are not split up here. The Leading cases tab lists the cases that cite it most heavily.

Show all 49 citing cases (list view) →

Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com